# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN-TD
- Date: 1896-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Higuchi is a 24-year-old writer with drug-susceptible pulmonary tuberculosis in the nineteenth week of treatment, now in the continuation phase on isoniazid, rifampin and pyridoxine by video-observed therapy, who comes for the preventive visit booked at her first appointment. Her cough and night sweats have gone, she sleeps well, and she has gained 4 kg since intake. The cystitis five weeks ago settled within two days on nitrofurantoin, and the culture grew Escherichia coli susceptible to it. The sputum culture taken at the end of the intensive phase showed no growth after six weeks. She writes about two hours each morning and has finished a new story. Public funding now covers most of her tuberculosis costs, and the social worker helped her arrange to pay her clinic charges in instalments. She has no new concerns. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 24 |
| Tuberculosis | Week 19 of 26; no symptoms; every dose taken |
| Cystitis | Resolved |
| Mood | PHQ-2 1; GAD-7 4 |

## Health risk assessment

Completed by the patient on paper in the waiting room and reviewed with her by Dr. Lindgren-Tanaka. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Money is her main stress; less worried now that treatment costs are covered; feels supported by her editors and readers |
| Substance use | AUDIT-C 0; no drug use |
| Tobacco | Never smoked; no one smokes at home |
| Physical activity | Walks to the market and back most days, about 30 minutes |
| Nutrition | Three meals and two snacks a day with two supplement drinks; more fish, eggs and tofu since the dietitian visits |
| Sleep | Seven hours; writing moved from night to morning |
| Safety | Feels safe at home; intimate partner violence screen negative; smoke alarm at home |
| Sexual and reproductive health | Not sexually active; not planning a pregnancy; regular periods |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss; weight rising |
| Eyes | Negative | No change in vision or color vision |
| Ears, nose, mouth, and throat | Negative | No sore throat or hearing change |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough, sputum or breathlessness |
| Gastrointestinal | Negative | No nausea, abdominal pain or jaundice |
| Genitourinary | Negative | No urinary symptoms since the cystitis; urine orange from rifampin |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash |
| Neurological | Negative | No numbness or tingling in the hands or feet |
| Psychiatric | Negative | Mood good; PHQ-2 1 |

11 systems reviewed. **S**

## Current medications

- Isoniazid 100 mg tablets, two tablets (200 mg) daily **S**
- Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 104/66 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 42.6 kg; BMI 19.4 kg/m². All vital signs are synthetic.

PHQ-2: 1; GAD-7: 4; AUDIT-C: 0. All results are synthetic.

## Change since baseline

- AUDIT-C: 0 at baseline, 0 at this visit **S**

## Immunizations given today

- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**
- Human papillomavirus 9-valent vaccine, dose 1 of 3 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Slim and well; weight 42.6 kg, BMI 19.4; blood pressure 104/66 |
| Eyes | No icterus; conjunctivae pink |
| Neck | No enlarged lymph nodes; thyroid normal |
| Respiratory | Clear on both sides |
| Cardiovascular | Regular rhythm; no murmur |
| Abdomen | Soft and non-tender; liver not enlarged |
| Genitourinary | Speculum examination with a small speculum, with a chaperone and her consent: normal cervix; cytology sample taken |
| Neurological | Normal sensation and reflexes in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. First cervical screening done. Tdap, the first hepatitis B dose and the first HPV dose given. HIV, hepatitis B and hepatitis C screening were done at intake. **S**
   - Cervical cytology result by phone; repeat in three years if normal.
   - Hepatitis B dose 2 and HPV dose 2 at the end-of-treatment visit; HPV dose 3 six months after the first.
   - Influenza vaccine at the end-of-treatment visit.
   - Next preventive visit in one year.
2. **Pulmonary tuberculosis, continuation phase** (A15.0). Week 19 of 26 with no symptoms. Rifampin speeds the breakdown of the hormones in combined pills, patches, rings and implants and makes them unreliable. **S**
   - If she needs contraception during treatment or for four weeks after, a copper IUD, an injectable progestin or condoms are reliable.
   - Continue every dose; end-of-treatment visit after the 182nd dose.
3. **Moderate protein-calorie malnutrition, improving** (E44.0). Weight 42.6 kg from 38.5 kg at intake; BMI 19.4. **S**
   - Continue the meal plan and supplement drinks until her weight reaches 44 kg.
4. **Low income** (Z59.6). Public funding covers most tuberculosis costs; clinic charges are paid in instalments. **S**
   - Social worker to review her costs again at the end of treatment.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 104/66 mmHg |
| Depression screening | Completed today | PHQ-2 score 1 |
| Anxiety screening | Completed today | GAD-7 score 4 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Asked privately; negative |
| Cervical cancer screening | Completed today | Cytology at 24, her first screening; every three years from 21 to 29 |
| Chlamydia and gonorrhea screening | Not indicated | Not sexually active; offer when that changes, as for sexually active women 24 or younger |
| Contraception and pregnancy intention | Completed today | Not planning a pregnancy; counseled on the rifampin interaction with hormonal methods |
| Folic acid | Completed today | Advised 0.4 to 0.8 mg daily, as for anyone who could become pregnant |
| HIV screening | Up to date | Negative at intake |
| Hepatitis C screening | Up to date | Negative at intake |
| Hepatitis B screening | Up to date | At intake: surface antigen, surface antibody and core antibody negative; not immune |
| Diabetes screening | Up to date | Hemoglobin A1c 5.1% at intake, checked because diabetes worsens tuberculosis outcomes |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap; no adult booster recorded |
| Hepatitis B vaccine | Completed today | Dose 1 of 2 today; dose 2 in eight weeks |
| HPV vaccine | Completed today | Catch-up dose 1 of 3 today, through age 26 |
| Influenza vaccine | Due | In the autumn, at the end-of-treatment visit |
| COVID-19 vaccine | Due | Discuss in the autumn |

## Advance care planning

Voluntary advance care planning discussion of about 16 minutes, with her consent. She understands that her tuberculosis is curable and wants full treatment of any illness. She named a health care agent, recorded in the confidential part of the chart and not named here, and chose to record no other preferences today. To be revisited yearly. **S**

## Guideline basis

- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- End-of-treatment visit after the 182nd dose, with the chest X-ray, blood tests, the second hepatitis B and HPV doses and the influenza vaccine. Cytology result by phone. Next preventive visit in one year. **S**
- Next scheduled visit 1896-10-20: end-of-treatment review after 182 doses. **S**
